We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tissue Regenix Group Plc | LSE:TRX | London | Ordinary Share | GB00BNTXR104 | ORD 0.1P |
Bid Price | Offer Price | High Price | Low Price | Open Price | |
---|---|---|---|---|---|
58.00 | 61.00 | 59.50 | 58.00 | 58.00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | USD 29.49M | USD -302k | USD -0.0043 | -138.37 | 40.93M |
Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
---|---|---|---|---|
16:35:26 | UT | 5,892 | 58.00 | GBX |
Date | Time | Source | Headline |
---|---|---|---|
13/12/2024 | 11:08 | UK RNS | Cavendish Securities PLC Form 8.5 (EPT/NON-RI) |
12/12/2024 | 10:19 | UK RNS | Cavendish Securities PLC Form 8.5 (EPT/NON-RI) |
11/12/2024 | 11:16 | UK RNS | Cavendish Securities PLC Form 8.5 (EPT/NON-RI) |
10/12/2024 | 12:15 | UK RNS | Lombard Odier Asset Mgt (Eur) Ltd. Form 8.3 - Tissue Regenix Group PLC |
09/12/2024 | 17:52 | UK RNS | Lexham Special Opportunities I LP Form 8.3 - Tissue Regenix Group plc |
09/12/2024 | 14:44 | UK RNS | Tissue Regenix Group PLC Holding(s) in Company |
09/12/2024 | 11:35 | UK RNS | Lombard Odier Asset Mgt (Eur) Ltd. Form 8.3 - Tissue Regenix Group PLC |
06/12/2024 | 13:57 | UK RNS | IP Group PLC Form 8.3 - Tissue Regenix Group plc |
05/12/2024 | 12:04 | UK RNS | Lombard Odier Asset Mgt (Eur) Ltd. Form 8.3 - Tissue Regenix Group PLC |
26/11/2024 | 07:00 | UK RNS | Tissue Regenix Group PLC Extended distribution agreement with Arthrex, Inc. |
Tissue Regenix (TRX) Share Charts1 Year Tissue Regenix Chart |
|
1 Month Tissue Regenix Chart |
Intraday Tissue Regenix Chart |
Date | Time | Title | Posts |
---|---|---|---|
25/11/2024 | 17:09 | Tissue Regenix delivering practical solutions to real clinical issues | 7,898 |
27/9/2021 | 17:42 | Tissue Regenix takes pole position in regeneration game | 2 |
26/5/2020 | 12:31 | Torex with Charts & News | 14 |
15/1/2020 | 07:09 | TOREX 2007 - THE TILLS RING AT LAST | 13 |
14/1/2020 | 20:51 | Terrane Minerals- Cu explorer, trading in Canada | 17 |
Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
---|---|---|---|---|
2024-12-13 16:35:26 | 58.00 | 5,892 | 3,417.36 | UT |
2024-12-13 16:07:40 | 58.00 | 142 | 82.36 | O |
2024-12-13 16:07:40 | 61.00 | 10 | 6.10 | O |
2024-12-13 16:07:40 | 58.00 | 1,422 | 824.76 | O |
2024-12-13 16:07:40 | 58.00 | 676 | 392.08 | O |
Top Posts |
---|
Posted at 13/12/2024 08:20 by Tissue Regenix Daily Update Tissue Regenix Group Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker TRX. The last closing price for Tissue Regenix was 58p.Tissue Regenix currently has 70,574,468 shares in issue. The market capitalisation of Tissue Regenix is £41,991,808. Tissue Regenix has a price to earnings ratio (PE ratio) of -138.37. This morning TRX shares opened at 58p |
Posted at 25/11/2024 16:21 by timmy40 Presumably the management are impatient with the share price. They have repositioned the company, increased the supply chain and revenue, but the share price has hardly moved for years now. They could always move the listing to the US, but a sale would seem like a reasonable option, although, we're not going to vote in favour without a decent premium imo |
Posted at 25/11/2024 08:33 by bamboo2 PJ84, I don't have email access during the day [no signal!], but can try later.I'll have a think how to angle it. I am almost certain that if they replied, I would not be allowed to share the info. I wonder if another route might be possible, via email to Research Tree or direct to significant investors in TRX? |
Posted at 24/11/2024 23:35 by pj84 bamboo2 TRX can and obviously have accessed the article they referred you to.Just checked the Betaville subscription rate and £5,000/qtr. (non-refundable is a bit steep for private investors) Maybe a polite follow up email might elicit a bit more information from TRX? |
Posted at 24/11/2024 22:42 by bamboo2 It does seem odd that TRX should take the opinion of one insignificant paywalled website so seriously. In this sort of situation the onus is on the company to bring ALL of the information into the public domain for the attention of ALL shareholders.I am probably being naïve, but it doesn't seem right that some of the information is only available to those with the means to pay for private access. |
Posted at 24/11/2024 22:25 by p1nkfish Looks dodgy all round. Hardly "media" that has much impact and TRX acting on it seems a little extreme. Anyone could set up a website and pass rumours.One take, if not a p&d is there is no smoke without fire but how would a paywalled site find out. Again, a bit dodgy. |
Posted at 24/11/2024 19:45 by pj84 bamboo2 thanks for postingI have tried to search for any other reference to the news and apart from the paywalled link the only other news I can find relates to the RNS that TRX issued which does seem strange. The major investors on the website as at 25 September owned just above 50% and to date I haven't seen any of them selling. If nothing happens then I suspect we won't hear anymore. |
Posted at 21/11/2024 12:20 by bamboo2 PJ/anyone Re, "Tissue Regenix (AIM: TRX), notes the media speculation and confirms that it is conducting a review of the Company's strategic options that may include soliciting offers for the Company. As part of this, the Company has contacted a limited number of potential counterparties to assess whether such parties could put forward a proposal that would deliver greater value to Tissue Regenix's shareholders than pursuing a standalone independent strategy."============= Have we had sight of, or a link to the media speculation? |
Posted at 04/11/2024 17:27 by bamboo2 I could find no media speculation with a quick google search.It does look to me like an offer has been made. Maybe it's too low? ==================== Response to media speculation Tissue Regenix (AIM: TRX), notes the media speculation and confirms that it is conducting a review of the Company's strategic options that may include soliciting offers for the Company. As part of this, the Company has contacted a limited number of potential counterparties to assess whether such parties could put forward a proposal that would deliver greater value to Tissue Regenix's shareholders than pursuing a standalone independent strategy. The Company has not received any indicative non-binding proposals to date. There can be no certainty that any offer will be made as a result of contact with these potential counterparties, nor as to the terms on which any such offer might be made. Shareholders are advised to take no action at this time. A further announcement will be made in due course. Takeover Code notes The Takeover Panel Executive has granted a dispensation from the requirement of Rules 2.4 (a) and (b) of the Takeover Code such that Tissue Regenix is not required to identify in this announcement any potential offeror with which the Company is in talks, or from which an approach has been received, unless that potential offeror has been specifically identified in any rumour or speculation. As a consequence of this announcement, an 'offer period' has now commenced in respect of the Company in accordance with the Takeover Code, and the attention of shareholders is drawn to the disclosure requirements of Rule 8 of the Takeover Code, which are summarised below in "Disclosure Requirements of the Takeover Code". |
Posted at 12/9/2024 08:40 by tnt99 We made a profit at last should this continue and accelerate should see some positive share price reaction Must be at least double this price to bring me back to where I started in 2018 Doh!!! |
Posted at 11/8/2022 10:11 by livewireplus :-)) unfortunately no refunds ... but had some good times ... have ended-up married - but as wife earns more than me then can't complain .... pass the Tissue from the left-hand side. An interesting week so far for the TRX share price .... |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions